Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom.
Loading...
Authors
Hanna, Daire
Merrick, Sophie
Ghose, Aruni
Devlin, Michael John
Yang, Dorothy D
Phillips, Edward
Okines, Alicia
Chopra, Neha
Papadimatraki, Elisavet
Ross, Kirsty
Issue Date
2024-04-24
Type
Journal Article
Multicenter Study
Multicenter Study
Language
en
Keywords
Wessex Classification Subject Headings::Oncology. Pathology.
Alternative Title
Abstract
Background: Treatment options for pre-treated patients with metastatic triple-negative breast cancer (mTNBC) remain limited. This is the first study to assess the real-world safety and efficacy of sacituzumab govitecan (SG) in the UK.
Methods: Data was retrospectively collected from 16 tertiary UK cancer centres. Pts had a diagnosis of mTNBC, received at least two prior lines of treatment (with at least one being in the metastatic setting) and received at least one dose of SG.
Results: 132 pts were included. Median age was 56 years (28-91). All patients were ECOG performance status (PS) 0-3 (PS0; 39, PS1; 76, PS2; 16, PS3;1). 75% (99/132) of pts had visceral metastases including 18% (24/132) of pts with CNS disease. Median PFS (mPFS) was 5.2 months (95% CI 4.5-6.6) with a median OS (mOS) of 8.7 months (95% CI 6.8-NA). The most common adverse events (AEs) were fatigue (all grade; 82%, G3/4; 14%), neutropenia (all grade; 55%, G3/4; 29%), diarrhoea (all grade; 58%, G3/4, 15%), and nausea (all grade; 38%, G3/4; 3%). SG dose reduction was required in 54% of pts.
Conclusion: This study supports significant anti-tumour activity in heavily pre-treated pts with mTNBC. Toxicity data aligns with clinical trial experience.
Description
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/
Citation
Hanna, D., Merrick, S.; Ghose, A.; Devlin, M. J.; Yang, D. D.; Phillips, E.; Okines, A.; Chopra, N.; Papadimatraki, E.; Ross, K.; Macpherson, I.; Boh, Z. Y.; Michie, C. O.; Swampillai, A.; Gupta, S.; Robinson, T.; Germain, L.; Twelves, C.; Atkinson, C.; Konstantis, A.; and Phillips, M. (2024) 'Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom', British Journal of Cancer. 130(12) pp..1916-1920. Available at: https://doi.org/10.1038/s41416-024-02685-9
Publisher
Nature
License
© 2024. The Author(s).
Journal
British journal of cancer
Volume
130
Issue
12
PubMed ID
ISSN
1532-1827